{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT03553875",
            "orgStudyIdInfo": {
                "id": "2018P001082"
            },
            "organization": {
                "fullName": "Massachusetts General Hospital",
                "class": "OTHER"
            },
            "briefTitle": "Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions",
            "officialTitle": "Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions: A Randomized-controlled Trial",
            "therapeuticArea": [
                "Other"
            ],
            "study": "memantine-for-the-treatment-of-social-deficits-in-youth-with-disorders-of-impaired-social-interactions"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2018-11-13",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-06",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-06",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2018-06-01",
            "studyFirstSubmitQcDate": "2018-06-01",
            "studyFirstPostDateStruct": {
                "date": "2018-06-12",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-27",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-28",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Gagan Joshi",
                "investigatorTitle": "Director, Autism Spectrum Disorder Program in Pediatric Psychopharmacology",
                "investigatorAffiliation": "Massachusetts General Hospital"
            },
            "leadSponsor": {
                "name": "Massachusetts General Hospital",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "This study is a 12-week randomized-controlled trial of memantine hydrochloride (Namenda) for the treatment of social impairment in youth with Non-Verbal Learning Disorder, High-Functioning Autism Spectrum Disorder, and related conditions. Eligible participants will be males and females ages 8-18.\n\nThis study consists of up to 6 visits to Massachusetts General Hospital."
        },
        "conditionsModule": {
            "conditions": [
                "Autism",
                "Autism Spectrum Disorder",
                "Nonverbal Learning Disability"
            ],
            "keywords": [
                "Autism",
                "Massachusetts General Hospital"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 100,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Memantine",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Memantine administered in tablet form twice daily titrated to a maximum dose of 20 mg for 12 weeks.",
                    "interventionNames": [
                        "Drug: Memantine Hydrochloride"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Subjects in the placebo control group will receive a matched placebo pill with no active ingredients. This will be administered twice daily for 12 weeks.",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Memantine Hydrochloride",
                    "description": "Participating children and adolescents with Non-Verbal Learning Disorder and related conditions (NVLD-RC) who meet the eligibility criteria will be randomly assigned to memantine for the course of the 12-week randomized controlled trial (RCT).",
                    "armGroupLabels": [
                        "Memantine"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Participating children and adolescents with Non-Verbal Learning Disorder and related conditions (NVLD-RC) who meet the eligibility criteria will be randomly assigned to placebo for the course of the 12-week randomized controlled trial (RCT).",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Clinical Global Impression-Improvement Scale (CGI-I)",
                    "description": "The Clinical Global Impression - Improvement scale (CGI-I) is a 7 point scale (1 to 7-- with higher numbers indicating more severely affected) that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention.",
                    "timeFrame": "Baseline to 12 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Male \\& female subjects ages 8-18 years (inclusive).\n* Diagnostic Statistical Manual (DSM)-5 Autism Spectrum Disorder (ASD) diagnostic criteria as established by clinical diagnostic interview\n* At least moderate severity of social impairment as measured by a total raw score of \u226585 on the parent/guardian-completed Social Responsiveness Scale-Second Edition (SRS-2)14 and a score of \u22654 on the clinician-administered Clinical Global Impression-Severity scale (CGI-S)17.\n\nExclusion Criteria:\n\n* IQ \u226470 based on the Wechsler Abbreviated Scale of Intelligence-II (WASI-II) Vocabulary and Matrix Reasoning subtests\n* Impaired communicative speech\n* Subjects currently treated with the following medications (known to impact glutamate levels): Lamotrigine, Amantadine, N-acetylcysteine, D-cycloserine\n* Subjects treated with a psychotropic medication not listed above on a dose that has not been stable for at least 4 weeks prior to study baseline.\n* Co-administration of drugs that compete with memantine for renal elimination using the same renal cationic system, including hydrochlorothiazide, triamterene, metformin, cimetidine, ranitidine, quinidine, and nicotine\n* Initiation of a new psychosocial intervention within 30 days prior to randomization.\n* Subjects who are pregnant and/or nursing.\n* Subjects with a history of non-febrile seizures without a clear and resolved etiology.\n* Subjects with a history of or a current liver or kidney disease.\n* Clinically unstable psychiatric conditions or judged to be at serious suicidal risk.\n* Subjects who meet on the Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS-E) for alcohol or drug dependence or abuse. If the subject has a recent history of substance abuse, there will be a two-week washout period before initiating the trial as an added precaution. There are no known safety issues relating to memantine and recent history of substance abuse.\n* Serious, stable or unstable systemic illness including hepatic, renal, gastroenterological, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease.\n* Subjects with severe hepatic impairment (LFTs \\> 3 times ULN).\n* Subjects with genitourinary conditions that raise urine pH (e.g., renal tubular acidosis, severe infection of the urinary tract).\n* Known hypersensitivity to memantine.\n* Severe allergies or multiple adverse drug reactions.\n* A history of intolerance or adequate exposure to memantine, as determined by the clinician.\n* Investigator and his/her immediate family defined as the investigator's spouse, parent, child, grandparent, or grandchild.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "8 Years",
            "maximumAge": "18 Years",
            "stdAges": [
                "CHILD",
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Meredith O'Connor, BS",
                    "role": "CONTACT",
                    "phone": "617-724-7301",
                    "email": "moconnor54@mgh.harvard.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Gagan Joshi, MD",
                    "affiliation": "Massachusetts General Hospital",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Massachusetts General Hospital",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02114",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Meredith O'Connor, BS",
                            "role": "CONTACT",
                            "phone": "617-724-7301",
                            "email": "moconnor54@mgh.harvard.edu"
                        },
                        {
                            "name": "Gagan Joshi, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "36006807",
                    "type": "DERIVED",
                    "citation": "Brignell A, Marraffa C, Williams K, May T. Memantine for autism spectrum disorder. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013845. doi: 10.1002/14651858.CD013845.pub2."
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000007859",
                    "term": "Learning Disabilities"
                },
                {
                    "id": "D000001321",
                    "term": "Autistic Disorder"
                },
                {
                    "id": "D000067877",
                    "term": "Autism Spectrum Disorder"
                },
                {
                    "id": "D000067404",
                    "term": "Social Communication Disorder"
                }
            ],
            "ancestors": [
                {
                    "id": "D000002659",
                    "term": "Child Development Disorders, Pervasive"
                },
                {
                    "id": "D000065886",
                    "term": "Neurodevelopmental Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                },
                {
                    "id": "D000003147",
                    "term": "Communication Disorders"
                },
                {
                    "id": "D000019954",
                    "term": "Neurobehavioral Manifestations"
                },
                {
                    "id": "D000009461",
                    "term": "Neurologic Manifestations"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4623",
                    "name": "Autistic Disorder",
                    "asFound": "Autism",
                    "relevance": "HIGH"
                },
                {
                    "id": "M206",
                    "name": "Autism Spectrum Disorder",
                    "asFound": "Autism Spectrum Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10872",
                    "name": "Learning Disabilities",
                    "asFound": "Learning Disabilities",
                    "relevance": "HIGH"
                },
                {
                    "id": "M141",
                    "name": "Social Communication Disorder",
                    "asFound": "Impaired Social Interactions",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6374",
                    "name": "Communication Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M5903",
                    "name": "Child Development Disorders, Pervasive",
                    "relevance": "LOW"
                },
                {
                    "id": "M5902",
                    "name": "Developmental Disabilities",
                    "relevance": "LOW"
                },
                {
                    "id": "M30644",
                    "name": "Neurodevelopmental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M21826",
                    "name": "Neurobehavioral Manifestations",
                    "relevance": "LOW"
                },
                {
                    "id": "M12404",
                    "name": "Neurologic Manifestations",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008559",
                    "term": "Memantine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000978",
                    "term": "Antiparkinson Agents"
                },
                {
                    "id": "D000018726",
                    "term": "Anti-Dyskinesia Agents"
                },
                {
                    "id": "D000015259",
                    "term": "Dopamine Agents"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018691",
                    "term": "Excitatory Amino Acid Antagonists"
                },
                {
                    "id": "D000018683",
                    "term": "Excitatory Amino Acid Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11542",
                    "name": "Memantine",
                    "asFound": "Peptic",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4295",
                    "name": "Antiparkinson Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M7473",
                    "name": "Dopamine",
                    "relevance": "LOW"
                },
                {
                    "id": "M17962",
                    "name": "Dopamine Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20771",
                    "name": "Excitatory Amino Acid Antagonists",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "AnDyAg",
                    "name": "Anti-Dyskinesia Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "CaAg",
                    "name": "Cardiotonic Agents"
                }
            ]
        }
    },
    "hasResults": false
}